Cardiovascular and pulmonary adverse events in patients treated withBCR-ABLinhibitors: Data from the FDA Adverse Event Reporting System
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular and pulmonary adverse events in patients treated withBCR-ABLinhibitors: Data from the FDA Adverse Event Reporting System
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 90, Issue 4, Pages E66-E72
Publisher
Wiley
Online
2015-01-08
DOI
10.1002/ajh.23938
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension
- (2013) Marius M. Hoeper et al. CIRCULATION
- Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System
- (2013) R Harpaz et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study
- (2013) Luciano Levato et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition
- (2013) Joanne A. Groeneveldt et al. EUROPEAN RESPIRATORY JOURNAL
- Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib
- (2013) J.-C. Kim et al. HERZ
- Data Mining of the Public Version of the FDA Adverse Event Reporting System
- (2013) Toshiyuki Sakaeda et al. International Journal of Medical Sciences
- Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
- (2013) T D Kim et al. LEUKEMIA
- Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis
- (2013) F J Giles et al. LEUKEMIA
- Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
- (2012) David Montani et al. CIRCULATION
- Nilotinib-Associated Vascular Events
- (2012) Alfonso Quintás-Cardama et al. Clinical Lymphoma Myeloma & Leukemia
- Pulmonary Arterial Hypertension Caused by Treatment with Dasatinib for Chronic Myeloid Leukemia -Critical Alert-
- (2012) Makoto Sano et al. INTERNAL MEDICINE
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
- (2012) R A Larson et al. LEUKEMIA
- The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database
- (2011) E. Raschi et al. ACTA DIABETOLOGICA
- Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML
- (2011) Karl J. Aichberger et al. AMERICAN JOURNAL OF HEMATOLOGY
- Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia
- (2011) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- The FDA Drug Safety Surveillance Program: Adverse Event Reporting Trends
- (2011) Sheila Weiss-Smith ARCHIVES OF INTERNAL MEDICINE
- Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia
- (2011) D. Dumitrescu et al. EUROPEAN RESPIRATORY JOURNAL
- Bone marrow necrosis secondary to imatinib usage, mimicking spinal metastasis on magnetic resonance imaging and FDG-PET/CT
- (2011) Yavuz Aras et al. JOURNAL OF NEUROSURGERY-SPINE
- Severe Peripheral Arterial Disease During Nilotinib Therapy
- (2011) P. Le Coutre et al. JNCI-Journal of the National Cancer Institute
- Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia
- (2011) Ester M. Orlandi et al. LEUKEMIA RESEARCH
- Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
- (2011) Jan K Hennigs et al. BMC Pulmonary Medicine
- Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy
- (2010) Hossein A. Ghofrani et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion
- (2009) Kimmo Porkka et al. CANCER
- Influence of the MedDRA® hierarchy on pharmacovigilance data mining results
- (2009) Ronald K. Pearson et al. INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS
- Quantitative signal detection using spontaneous ADR reporting
- (2009) A. Bate et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient
- (2008) D Mattei et al. BONE MARROW TRANSPLANTATION
- Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia
- (2008) Walid Rasheed et al. LEUKEMIA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started